Danaher (DHR) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
13 Oct, 2026Financial and operating update
Q2 core growth 7.5%; core operating margin +160 bps YoY; adjusted EPS nearly +30% YoY.
Q3 outlook reiterated at 6%–8% core growth and $0.66–$0.71 EPS; July and August tracked expectations, with modest impact from market headlines.
Emerging markets led geographic growth through the first two months of Q3; U.S. performance remained ahead of Europe.
Planning at least $50 million of quiet restructuring in Q4, excluding Beckman Coulter; Beckman’s cost program targets $250 million in savings and includes a 1,000-person reduction underway in Q3.
Emerging-market strategy and investment
Emerging markets represented 22% of revenue, or $4 billion pro forma with Beckman Coulter; longer-term ambition is 30% through stronger local execution.
Low-cost-region sourcing reached nearly 30%, double the 2005 level; China exports were approaching $800 million.
More than 1,200 engineers and scientists in emerging markets worked on development projects; 2010 hiring additions were weighted to growth roles and emerging markets.
Strategy combines local teams, distribution, service, sourcing and R&D with localized mid- and opening-price products; newer businesses and life sciences remain under-penetrated.
Nine emerging-market transactions were completed over five years; Beckman Coulter brought 22% emerging-market sales and a $300 million China business.
China and India
China served market was about $7 billion, with almost $2 billion in sales and low-double-digit growth; its footprint included nearly 800 engineers and about 10 manufacturing facilities.
China localization and expanded mid-price offerings supported share gains; Fluke brand awareness reached the 70% range, while second- and third-tier city coverage expanded.
China’s local R&D center had 800+ engineers across 15 operating companies and was estimated to cut launch time by one to two years for new entrants.
India served market was $2 billion, with low-double-digit growth; the footprint had expanded to 700+ associates, two manufacturing sites and 300+ R&D associates.
India coverage exceeded 200 cities; Fluke distributor street coverage rose over 33%, and its H1 sales growth exceeded 50% after targeted expansion.
Latest events from Danaher
- Q3 sales and adjusted EPS grew; FY 2026 EPS guidance rose to $8.57–$8.62.DHR
Q3 2026 - Q2 2026 revenue up 5.5%, net earnings $870M, and full-year EPS guidance raised.DHR
Q2 2026 - All board nominees, auditor appointment, and executive pay were approved by large majorities.DHR
AGM 2025 - All proposals passed with strong support amid robust financial performance and strategic focus.DHR
AGM 2026 - Strong growth in bioprocessing and diagnostics supports a positive full-year outlook.DHR
Bank of America Global Healthcare Conference 2026 - Bioprocessing and diagnostics drive growth outlook, with Masimo acquisition boosting long-term returns.DHR
TD Cowen 46th Annual Health Care Conference - Q1 2026 revenue up 3.5% to $6.0B, adjusted EPS up 9.5%, Masimo acquisition announced.DHR
Q1 2026 - Strong 2025 results, robust recurring revenue, and innovation drive long-term growth outlook.DHR
Corporate presentation - Strong Q4 results, robust recurring revenue, and high single-digit growth outlook driven by innovation.DHR
43rd Annual J.P. Morgan Healthcare Conference 2025